Enliven Therapeutics, Inc.
ELVN
$18.73
-$0.08-0.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.56M | 23.78M | 21.13M | 18.66M | 16.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.26M | 104.55M | 99.09M | 94.97M | 89.20M |
| Operating Income | -110.26M | -104.55M | -99.09M | -94.97M | -89.20M |
| Income Before Tax | -94.60M | -88.79M | -84.98M | -82.60M | -79.60M |
| Income Tax Expenses | 232.00K | 232.00K | 232.00K | 232.00K | -- |
| Earnings from Continuing Operations | -94.83 | -89.02 | -85.21 | -82.83 | -79.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.83M | -89.02M | -85.21M | -82.83M | -79.60M |
| EBIT | -110.26M | -104.55M | -99.09M | -94.97M | -89.20M |
| EBITDA | -109.95M | -104.24M | -98.77M | -94.65M | -88.89M |
| EPS Basic | -1.93 | -1.90 | -1.91 | -1.93 | -1.93 |
| Normalized Basic EPS | -1.21 | -1.20 | -1.17 | -1.17 | -1.14 |
| EPS Diluted | -1.93 | -1.90 | -1.91 | -1.93 | -1.93 |
| Normalized Diluted EPS | -1.21 | -1.20 | -1.17 | -1.17 | -1.14 |
| Average Basic Shares Outstanding | 196.25M | 188.25M | 179.52M | 172.28M | 165.17M |
| Average Diluted Shares Outstanding | 196.25M | 188.25M | 179.52M | 172.28M | 165.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |